Secure Drug Supply Chain Act of 2026

This bill directs the Department of Health and Human Services to use its existing drug-safety powers to stop imports of counterfeit, unapproved, mislabeled, or contaminated drugs and drug ingredients, with a focus on China and other countries the State Department labels adversarial. Drug makers would have to report their drug listings quarterly instead of yearly and disclose the identity, amount, and country of origin of drug ingredients sourced from China or other countries of concern. The bill would bar imports of drugs made in facilities known to use forced labor or violate federal sanctions, and drugs whose safety rests only on foreign government inspections without routine U.S. inspections. It would also let the government order the destruction of refused imports that raise a significant public health concern, at the owner's cost, and would require yearly reports to Congress on enforcement and supply chain dependence.

Full text and official record on Congress.gov

Sponsors

• Ted Budd Republican sponsor
• 2 cosponsors